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Measurement of soluble CD59 in CSF in demyelinating disease: evidence for an intrathecal 
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
Background: CD59, a broadly expressed glycosylphosphatidylinositol (GPI) anchored protein, is the prin-
ciple inhibitor of complement membrane attack on cells. In the autoinflammatory demyelinating disor-
ders, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), elevated comple-
ment protein levels were reported in cerebrospinal fluid (CSF), including soluble (s)CD59 in CSF. 
Objectives: We compared levels of sCD59 in CSF and matched plasma in controls and patients with MS, 
NMOSD, and clinically isolated syndrome (CIS), investigated the source of sCD59 in CSF and whether it 
was microparticle-associated.  
Methods: sCD59 was quantified using ELISA (Hycult Biotech; HK374-02). Patient and control CSF was 
subjected to western-blotting to characterise anti-CD59-reactive materials. CD59 was localised by im-
munostaining. 
Results: CSF sCD59 levels were double those in plasma (sCD59 in CSF= 30.2ng/ml, plasma= 16.3ng/ml; 
n= 91). sCD59 levels in plasma, but not CSF, differentiated MS from NMOSD, MS from CIS, and 
NMOSD/CIS from controls. Centrifugation to remove microparticles demonstrated that ˃85% of CSF 
CD59 was not membrane anchored. 
Conclusions: High levels of sCD59 in CSF relative to plasma suggest an intrathecal source; CD59 expres-
sion in brain parenchyma was low but expression was strong on choroid plexus (CP) epithelium, imme-
diately adjacent the CSF space, suggesting that this is the likely source. 




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

The complement system is a central component of innate immunity responsible for recognition 
and killing of bacteria by lysis and promoting phagocytosis through opsonisation. The main 
source of most complement proteins is the liver, however other cells, including fibroblasts, 
epithelial and endothelial cells, glia and neurons, also produce complement proteins.
1
 Activation 
of complement via the classical, lectin or alternative pathway leads to the formation of C3 
convertase complexes that cleave C3 to C3a and C3b. C3b is the nidus for the C5 convertase that 
cleaves C5 to C5a and C5b, the latter initiating formation of the membrane attack complex 
(MAC) responsible for osmotic cell lysis. CD59, an ~18–20 kDa GPI anchored protein, regulates 
formation of MAC by preventing recruitment of C9. 
2
 Little is known about expression of CD59 
in the brain; in one study neurones were reported to lack CD59 and expression of CD59 on glia 
was increased in inflamed brain.
3
 The blood–brain barrier (BBB) restricts entry of molecules into 
the central nervous system (CNS), providing a natural defence against circulating toxic or 
infectious agents.
4 
The choroid plexus (CP) plays a crucial role in the production of CSF, and 
may be a site of immune activation; for example, in a mouse model of human systemic lupus 
erythematosus (SLE), dense deposits of immunoglobulin G (IgG) and C3 were found in the CP.
5 
More recently the role of CP in cellular immunology became more evident with the 
demonstration that CP was responsible for controlling and development of immune responses in 
the CNS.
6
 Recent immunohistochemical (IHC) data on human CP showed deposition of 
complement proteins; C1q, C3d, and C9 in stromal concretions and IgG in epithelial cells, 
suggesting significant involvement of CP in clearance of complement:tagged immune 
complexes.
7
 Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and 
clinically isolated syndrome (CIS) are autoinflammatory demyelinating brain disorders in which 
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dysregulation of complement has been noted in CSF, plasma and brain.
8:15
 It was recently 
reported that soluble (s) CD59 is increased in CSF in MS and NMOSD.
16
 This finding prompted 
us to further investigate levels of sCD59 in CSF and plasma from MS, NMOSD and CIS cases 
and healthy controls with the aim of gaining insight into underlying pathology. sCD59 was 
measured using a commercial ELISA and the nature of sCD59 in CSF, microparticle:associated 
or free, was explored. To discover the source of sCD59 in CSF we analysed brain CD59 
expression by IHC. 
 
 



All chemicals, except where otherwise stated, were obtained from either Fisher Scientific UK 
(Loughborough, Leicestershire, UK) or Sigma Aldrich (Gillingham, Dorset, UK) and were of 
analytical grade. 

Subjects 
 
	

CSF Samples from 50 MS patients, 11 NMOSD patients, 17 CIS patients, and 34 controls and 
matched Ethylenediaminetetraacetic acid (EDTA) plasma samples from 41 MS patients, 10 
NMOSD, 14 CIS patients and 26 controls were obtained from the Welsh Neuroscience Research 
Tissue Bank, Institute of Neurosciences and Mental Health, Cardiff University. Mean age and % 
Female were as follow; MS; 45, 68%, NMOSD; 49, 80%, CIS; 43, 78%, Controls; 32, 77%. 
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Ethnicity was reported in the majority of patients as Caucasian (two cases were non:Caucasian; 
one each of MS and NMOSD). Informed consent was obtained from all patients, and ethical 
approval was gained from South East Wales Ethics Committee (ref no. 05/WSE03/111). 
Diagnosis for MS cases was made according to established criteria
17
; all had clinically definite 
disease and had exhibited a relapsing disease course for which comprehensive follow:up clinical 
data was available. In addition all MS cases had undergone diagnostic and follow:up magnetic 
resonance imaging (MRI) as part of routine clinical care. All patients with NMOSD were 
reviewed and diagnosis confirmed according to established criteria
18
 by a neurologist with 
experience in the diagnosis and management of neuroinflammatory disorders including 
NMOSD. All NMOSD cases had undergone diagnostic and follow:up MRI as part of routine 
clinical care. AQP4:Ab and MOG:Ab status was assessed at the Clinical Neuroimmunology 
Service, John Radcliffe Hospital Trust, Oxford, UK.
19, 20
 
 
	

	
MS (n=5 cases) and non:neurological control (n=7 cases) post:mortem tissue was provided by 
the UK Multiple Sclerosis Society Tissue Bank at Imperial College and the Oxford Brain Bank 
at Oxford University, with research ethical approval (South West Wales REC study 
12/WA/0292). Six micron thick sections were prepared from a single region:matched paraffin:
embedded block per case of the anterior hippocampus at the level of the lateral geniculate 
nucleus. All sections assessed contained intact meninges and choroid plexus (of the inferior horn 
of the lateral ventricle). Case details are listed in Table 1.   

		
 	!
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The concentration of sCD59 in CSF and plasma samples was measured using a commercial 
ELISA (Hycult Biotech, HK374:02, Uden, The Netherlands). Levels of sCD59 in CSF, 
unfractionated and following high:speed centrifugation (21200 rcf for 5 minutes at room 
temperature) to remove microparticles, were compared in a subset of 23 samples. 

$!%&	
	'
Patient and control CSF was subjected to SDS/PAGE and western blotting to further characterise 
anti:CD59:reactive materials in CSF. Prior to analysis the patient CSF samples (MS and 
NMOSD) were 10:fold concentrated using Vivaspin sample concentrators (GE Healthcare, 
Amersham Place, Little Chalfont, UK, cut:off size; 10 kDa). As a positive control, human 
erythrocyte membraners, prepared by lysing erythrocytes in deionised water, centrifuging and 
washing the membrane pellet in PBS, were solubilised in non:reducing sample buffer (0.1M 
Tris, 10% w/v glycerol, 2% w/v SDS, bromophenol blue, pH 6.8 in deionised water). Undiluted 
plasma or CSF samples were mixed 1 in 5 with non:reducing sample buffer. All samples were 
resolved on 4 – 20% gradient SDS:PAGE gels (Biorad; 456:1094); then electrophoretically 
transferred onto 0.45 Hm nitrocellulose membrane (GE Healthcare, Amersham, UK, 10600002) 
at a constant voltage of 90 V in 25mM Tris, 19.2mM Glycine buffer with 20% methanol. After 
transfer, non:specific sites on the membrane were blocked with 3% BSA in PBS for 1 h at room 
temperature (RT). All subsequent incubations were carried out for 1 hour at RT and followed by 
three washes with PBS containing 0.1% Tween:20 (PBS:T). Post:blocking, the membrane was 
incubated with the primary antibody, monoclonal anti:human CD59 (MEM43 at 1µg/ml in PBS:
T). After washing, the bound antibodies were revealed by incubation with donkey anti:mouse 
IgG:HRP conjugate (Jackson Immunoresearch, 715:035:151) at an optimized dilution of 1:2000 
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in PBS:T. The blot was developed with ECL (GE Healthcare, Amersham, UK, RPN 2106) and 
visualised by autoradiography. 


	


 
Sections were de:waxed, rehydrated, and subjected to heat:induced epitope retrieval in citraconic 
anhydride (0.05%), then quenched in H2O2 and blocked with normal serum before overnight 
incubation with monoclonal (MEM43) or rabbit polyclonal anti:CD59 antibody. Bound primary 
antibody was detected using the appropriate biotinylated goat secondary antibody (Vector Labs) 
prior to incubating with the Avidin:biotin HRP complex (ABC Elite; Vector Labs). Staining was 
visualised using diaminobenzidine (Impact DAB; Vector) and all sections were counterstained 
with haematoxylin before dehydrating, clearing and mounting in DePex (Fisher Scientific). No:
primary:antibody and irrelevant mouse or rabbit antibodies were included as staining controls 
and all sections were immunostained in the same experimental run. Sections were viewed and 
images captured using a Zeiss Axio Imager II fitted with an AxioCam HR camera (Carl Zeiss 
Ltd.). The relative intensity of CD59 immunoreactivity (mouse monoclonal antibody MEM43) in 
the choroid plexus, ependyma, meninges, vasculature and brain parenchyma was evaluated as: 0, 
absent; +, mild (very few stained cells or weakly stained structures); ++, moderate (30:70% of 
cells immunopositive or structures showing intermediate immunopositivity); +++, substantial 
(majority of cells or tissues are intensely immunopositive). 
 


	(	
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Soluble CD59 was detected in all CSF and plasma samples tested; levels in CSF were 
approximately double those in matched plasma (Figure 1A; p<0.0001). There was no significant 
difference in CSF sCD59 levels between the various disease groups (Figure 1B); however, 
measurement of sCD59 in plasma differentiated MS from NMOSD (p<0.005), MS from CIS 
(p<0.003) and NMO/CIS from controls (P ˂ 0.003) (Figure 1C). The data confirm that the 
observed ratios between CSF and plasma sCD59 levels were consistent across the groups (Figure 
1D).  
 
*	+)	
		
,
sCD59 can exist in biological fluids either as an anchor:free soluble small molecule or as a GPI:
anchor intact lipid/microparticle:associated molecule.
21
 To test the nature of sCD59 found in 
CSF, those samples available in sufficient volume (23) were subjected to high speed 
centrifugation to remove microparticles and sCD59 concentration was measured prior to and 
after centrifugation. Levels of sCD59 in centrifuged CSF were not significantly different 
compared to uncentrifuged (mean concentration before centrifugation 32.5ng/ml; after 
centrifugation 28.1ng/ml), confirming that majority of the CD59 (˃85%) in CSF is not anchored 
to microparticles (Figure 2). As an independent verification of this finding, CSF was passed 
through a 0.2µM filter; sCD59 level was not significantly altered by filtration (data not 
included).   
 

				

	
	
	 	
	

	,
The nature of the sCD59 reactivity in MS, NMOSD and control CSF samples was tested by 
western blot analysis. In each sample tested, CSF sCD59 comprised a broad band of 19:23 kDa, 
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slightly higher in MW and more compact than the band obtained in erythrocyte lysates and 
resembling published data on nucleated cell:derived CD59.
22
 (Figure 3 A, B). 

*		-
 (
				,
Using a mouse monoclonal antibody to CD59 we demonstrated strong anti:CD59 
immunoreactivity at the brain:CSF and brain:blood barriers of the human brain. Anti:CD59 
immunoreactivity was comparable between MS (Fig 4A, B) and non:inflammatory control brains 
(Fig 4C, D) and was notable in the parenchymal vasculature (both arteries and veins), meningeal 
vasculature, ependymal lining of the ventricles and the choroid plexus epithelium (Figure 4). In 
contrast to the modest to substantial immunoreactivity of these structures, cell:specific staining 
within the hippocampus and parahippocampal grey and white matter was absent or weak. This 
pattern of CD59 expression was verified using a polyclonal anti:CD59 antibody raised in rabbit 
(Fig 4K).    



Measurement of complement proteins, regulators and activation products in CSF has been 
described in several studies and proposed as contributory biomarkers in demyelinating and 
degenerative neurological diseases. Levels of C3 and FH were reduced in Alzheimer’s disease 
CSF and correlated with disease staging.
23
 The soluble terminal complex sC5b:9 was increased 
in CSF in both MS and NMOSD, more so in the latter, indicating more complement activation.
24
 
Soluble complement receptor 2 (sCR2) levels were increased in MS CSF and suggested to be of 
functional relevance but its source was not explored.
25
  A recent study reported that levels in 
CSF of the soluble form of the GPI:anchored cell surface complement regulator CD59 (sCD59) 
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were significantly elevated in MS and NMOSD compared to non:inflammatory neurological 
disease controls provoked our interest.
16
 We set out to replicate these findings in a larger sample 
and to explore the source of sCD59 in CSF.     
 
Expression of complement regulators, including CD59, in the human brain has been the subject 
of previous work. CD59 expression in the normal, non:inflamed brain is very low with minimal 
expression on glia and negligible expression on neurones.
3
 The only sites in the normal brain 
where CD59 is abundantly expressed are the vascular endothelium and the choroid plexus where 
CD59 is reported to decorate the apical surface of the ependymal cells.  In the inflamed brain, 
expression of complement regulators, including CD59, is increased, although levels remain low 
compared to the periphery.
26
 It is likely that this increase in regulator expression is a homeostatic 
response as levels of complement proteins are increased in the inflamed brain due either to 
intrathecal production or transudation of complement proteins across the leaky BBB.
27
 
 
We measured sCD59 levels in CSF from 50 MS, 11 NMOSD and 17 CIS patients, and 34 non:
inflammatory controls. CSF sCD59 levels were ~30ng/ml in the samples and were not different 
between the groups; in particular, levels were not higher in MS and/or NMO compared to 
controls in contrast to recent report.
16
 In 91 of the available cases, matched plasma taken at the 
time of lumbar puncture was available; in these we measured plasma sCD59 levels in the same 
assay. Plasma sCD59 levels were, on average, around half that in matched CSF samples (mean 
sCD59 in CSF = 30.2ng/ml, plasma = 16.3ng/ml (n = 91). Plasma sCD59 levels were 
significantly higher in MS and controls compared to NMOSD and CIS.   
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Our findings do not support the published work describing CSF sCD59 as a powerful biomarker 
of NMOSD and MS.
16
 The reasons for this failure to replicate are uncertain.  Our cohort was 
overwhelmingly comprised of Caucasians with well:characterised disease followed up over a 
prolonged period; the published study was from Japan and thus was very different in terms of 
ethnicity. We used a commercial assay using validated anti:CD59 monoclonal antibodies and a 
recombinant protein standard; the published study used a different commercial CD59 ELISA 
assay (by MyBioSource, Inc., detection range; 31.25–2000 pg/ml) with no details of its 
architecture. Our measured values were approximately 100:fold higher than those in the previous 
report (~30ng/ml cf. ~300pg/ml); of note, our ability to detect sCD59 by western blotting in 10:
fold concentrated CSF supports our finding of higher levels.  
 
CD59 is a GPI:anchored membrane:associated molecule and its appearance in the fluid phase 
requires either shedding on lipid vesicles with an intact GPI anchor or enzymatic anchor 
cleavage and release as a soluble, unanchored molecule; sCD59 in urine has been shown to be 
anchor:free, likely derived by enzymatic cleavage from renal tubular cells.
28:30
 In order to 
investigate the nature of sCD59 in CSF we performed high:speed centrifugation to remove 
microparticles and re:measured sCD59 in a subset of CSF samples. Measured levels were little 
affected by centrifugation, indicating that CSF sCD59 was anchor free; this was further 
confirmed by showing that passage of the few CSF samples available in sufficient quantities 
through a 0.2µM filter did not reduce measured sCD59 levels. Characterisation of sCD59 by 
western blotting showed that it ran as a 19:23kDa band closely resembling published blots of 
urine:derived CD59.
31
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To explore the source of sCD59 in CSF we stained human brain sections; as previously reported, 
CD59 staining in brain parenchyma was restricted to vessel endothelium and lumen. In sharp 
contrast, choroid plexus staining was abundant, co:localised with vessels and with ependyma, 
specialised glial cells responsible for production of the CSF. We suggest that enzymatic shedding 
from this surface represents the likely source of CSF sCD59.  
 
A surprising finding was that CSF levels of sCD59 were much higher than in matched plasma. A 
possible explanation of this is that although sCD59 might be generated in peripheral tissues, its 
small size when anchor:free means that it is excreted first:pass through the kidney where it 
accumulates in urine; in CSF, sCD59 accumulates because the BBB is impermeant to molecules 
larger than 600 Da.
32
 Whether the (relatively) high amounts of sCD59 in CSF are of any 
functional relevance remains to be demonstrated. In principle, sCD59 might contribute to 
homeostasis by dampening down complement activation in the CSF; however, in other 
biological fluids sCD59 is a poor regulator because it associates with other proteins.
33
 
 
In conclusion, we show that a non:anchored soluble form of sCD59 is present in CSF in health 
and neuroinflammatory diseases at similar levels, that CSF levels of sCD59 are consistently 
higher than in matched plasmas and that the likely source of CSF sCD59 is the choroid plexus, a 
site of abundant expression in the normal and inflamed brain.     
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Table 1: Details 
of the cases 
used for IHC in 
this study.  
 
 
 
 
 
 
 
 
 
 
 
All cases were pathologically confirmed as progressive MS or as non-neurological, non-
neuroinflammatory controls (Ctrl). PMD; post-mortem delay. 
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Table 1. Details of the cases used for IHC in this study. All cases were pathologically 
confirmed as progressive MS or as non!neurological, non!neuroinflammatory controls (Ctrl). 
PMD; post!mortem delay. 
 
Figure 1. Measuring sCD59 in CSF and matched plasma samples. A)  sCD59 is measureable 
in all plasma and CSF samples tested and are ~2!fold lower in plasma compared to CSF. B) 
CSF levels of sCD59 were not significantly different between the individual groups; MS, 
NMOSD, CIS or Controls. C) Plasma levels of sCD59 in MS, NMOSD and CIS patients 
compared with normal controls differentiate MS from NMOSD (p<0.005), MS from CIS and 
NMOSD/CIS from controls (p<0.003). D). Summary of the data.  
Figure 2. Measurement of sCD59 in CSF; samples from 23 individuals (MS=9, NMOSD=2, 
CIS=4, control=8) were measured before (unspun) and after (spun) high!speed centrifugation; 
no significant difference seen in sCD59 levels between both groups (mean; unspun: 
28.1ng/ml, spun: 32.5ng/ml). 
 
Figure 3. Detection of sCD59 in CSF patient samples using western blot; CSF samples were 
concentrated x 10. (MS=3, NMOSD=3, Control=6). A) Samples with higher concentrations 
of sCD59 as measured in the ELISA (NMOSD, Control), B); Samples with lower 
concentration of sCD59 in ELISA (MS and Control). In all cases, 10!fold concentrated 
sample (25µl per line) was resolved on 4!20% gradient PAGE under non!reducing conditions 
and processed for western blot with MEM43 (monoclonal anti!CD59). MS; Multiple 
Sclerosis, NMOSD; Neuromyelitis Optica Spectrum Disorder, CIS; Clinically Isolated 
Syndrome, CTR; Control, Hu EA(+)Ctr; CD59 positive human erythrocyte lysate.  
 
Page 19 of 23
http://mc.manuscriptcentral.com/multiple-sclerosis
Multiple Sclerosis Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
Figure 4. CD59 is expressed at vessel luminal surfaces and by cells lining the choroid plexus 
and ventricle wall. Immunohistochemistry of formalin!fixed paraffin embedded MS and 
control hippocampus revealed strong staining with monoclonal anti!CD59 in the vasculature 
of the meninges (A! D), parenchymal vessels (E, F), cells of the ventricle wall (ependyma of 
the inferior horn of the lateral ventricle (G, H) and epithelial cells of the choroid plexus (I, J). 
An identical pattern of staining was seen with a polyclonal anti!CD59 antibody (K). Staining 
with an irrelevant mouse (L) or rabbit (not shown) IgG was negative. All images captured 
with a 10x (A, C, E, G, I) or 40x (B, D, F, H, J, K, L) objective. Scale bar= 50µm shown in A 
and B.   

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